TrialmAbs2026

Safety, tolerability, and pharmacokinetics/-dynamics of the dipeptidyl peptidase 3-inhibiting antibody Procizumab in a first-in-human trial.

Dirk van Lier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.